Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF

被引：0
|
作者：
Adamson, C. [1 ]
Welsh, P. [1 ]
Morrow, D. A. [2 ]
Docherty, K. F. [1 ]
Hammarstedt, A. [3 ]
Inzucchi, S. E. [4 ]
Kober, L. [5 ]
Kosiborod, M. N. [6 ]
Martinez, F. A. [7 ]
Ponikowski, P. [8 ]
Sabatine, M. S. [2 ]
Solomon, S. D. [2 ]
Sattar, N. [1 ]
Jhund, P. S. [1 ]
McMurray, J. J. V. [1 ]
机构：
[1] Univ Glasgow, Glasgow, Lanark, Scotland
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] AstraZeneca, Gothenburg, Sweden
[4] Yale Univ, New Haven, CT USA
[5] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[6] Univ Missouri, Kansas City, KS USA
[7] Natl Univ Cordoba, Cordoba, Argentina
[8] Wroclaw Med Univ, Wroclaw, Poland
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：913 / 913
页数：1
相关论文
共 50 条
  • [21] Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF (vol 142, 1040, 2020)
    Jackson
    CIRCULATION, 2020, 142 (20)
  • [22] Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial
    Butt, Jawad H.
    Nicolau, Jose C.
    Verma, Subodh
    Docherty, Kieran F.
    Petrie, Mark C.
    Inzucchi, Silvio E.
    Schou, Morten
    Kosiborod, Mikhail N.
    Langkilde, Anna Maria
    Martinez, Felipe A.
    Ponikowski, Piotr
    Sabatine, Marc S.
    Sjostrand, Mikaela
    Solomon, Scott D.
    Bengtsson, Olof
    Jhund, Pardeep S.
    McMurray, John J. V.
    Kober, Lars
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (04) : 601 - 613
  • [23] GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL
    Berg, David
    Docherty, Kieran F.
    Talebi, Atefeh
    Sattar, Naveed
    Jarolim, Petr
    Welsh, Paul
    Jhund, Pardeep
    Anand, Inderjit S.
    De Boer, Rudolf A.
    Kosiborod, Mikhail
    Kober, Lars
    Martinez, Felipe A.
    O'Meara, Eileen
    Ponikowski, Piotr
    Schou, Morten
    Solomon, Scott D.
    Hammarstedt, Ann
    Langkilde, Anna Maria
    McMurray, John J. V.
    Sabatine, Marc Steven
    Morrow, David A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 631 - 631
  • [24] Translating findings from the landmark DAPA-HF study: a multinational cost-effectiveness analysis of dapagliflozin in the treatment of heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Mcewan, P.
    Darlington, O.
    Jhund, P.
    Docherty, K.
    Bohm, M.
    Petrie, M.
    Bergenheim, K.
    Qin, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 272 - 273
  • [25] Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
    Docherty, Kieran F.
    Welsh, Paul
    Verma, Subodh
    De Boer, Rudolf A.
    O'Meara, Eileen
    Bengtsson, Olof
    Kober, Lars
    Kosiborod, Mikhail N.
    Hammarstedt, Ann
    Langkilde, Anna Maria
    Lindholm, Daniel
    Little, Dustin J.
    Sjostrand, Mikaela
    Martinez, Felipe A.
    Ponikowski, Piotr
    Sabatine, Marc S.
    Morrow, David A.
    Schou, Morten
    Solomon, Scott D.
    Sattar, Naveed
    Jhund, Pardeep S.
    McMurray, John J., V
    CIRCULATION, 2022, 146 (13) : 980 - 994
  • [26] High-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial
    Berg, David D.
    Sabatine, Marc S.
    Sattar, Naveed
    Jarolim, Petr
    Welsh, Paul
    Jhund, Pardeep S.
    Anand, Inder
    De Boer, Rudolf A.
    Kosiborod, Mikhail
    O'Meara, Eileen
    Hammarstedt, Ann
    CIRCULATION, 2021, 144
  • [27] Influence of Ejection Fraction on the Effect of Treatment in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF)
    Solomon, Scott
    DeMets, David L.
    Inzucchi, Silvio E.
    Kober, Lars
    Kosiborod, Mikhail N.
    Langkilde, Anna Maria
    Martinez, Felipe
    Bengtsson, Olof
    Ponikowski, Piotr
    Sabatine, Marc S.
    Sjostrand, Mikaela
    McMurray, John J.
    CIRCULATION, 2019, 140 (25) : E973 - E973
  • [28] Budget impact evaluation of the DAPA-HF trial: is dapagliflozin cost-saving for the treatment of heart failure with reduced ejection fraction?
    Qin, L.
    Darlington, O.
    Miller, R.
    Mellstrom, C.
    Mcewan, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 305 - 305
  • [29] Acute changes in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF
    Docherty, K. F.
    Vaduganathan, M.
    Inzucchi, S. E.
    Kober, L.
    Kosiborod, M. N.
    Martinez, F. A.
    Bengtsson, O.
    Ponikowski, P.
    Sabatine, M. S.
    Sjostrand, M.
    Solomon, S. D.
    Langkilde, A. M.
    Jhund, P. S.
    Mcmurray, J. J. V. John J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 57 - 57
  • [30] Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial
    Butt, J. H.
    Dewan, P.
    Docherty, K.
    Inzucchi, S.
    Ponikowski, P.
    Martinez, F.
    Bengtsson, O.
    Sjostrand, M.
    Solomon, S. D.
    Sabatine, M.
    Kosiborod, M.
    Langkilde, A. M.
    Jhund, P. S.
    Kober, L.
    Mcmurray, J. J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 138 - 139
12345